Top

Published in:

01-09-2009 | Current concepts in Endocrine Surgery

Hyperparathyroidism–jaw tumor syndrome: a report of three large kindred

Authors: Maurizio Iacobone, Giulia Masi, Luisa Barzon, Andrea Porzionato, Veronica Macchi, Francesco Antonio Ciarleglio, Giorgio Palù, Raffaele De Caro, Giovanni Viel, Gennaro Favia

Published in: Langenbeck's Archives of Surgery | Issue 5/2009

Abstract

Background

Hyperparathyroidism–jaw tumor syndrome (HPT–JT) is a rare autosomal disease caused by inactivating germ-line mutations of HRPT2 gene, with subsequent loss of Parafibromin expression. It is characterized by familial HPT, ossifying jaw tumors, and other associated neoplasms.

Methods

Clinical, histopathological, and genetic features of three large Italian unrelated HPT–JT kindred were assessed.

Results

Three different germ-line HRPT2 inactivating mutations were identified. Seventeen affected members and six healthy mutation carriers were found. HPT was diagnosed in virtually all affected patients, at a median age of 36.3 years (range 11–71). In all cases, a single parathyroid involvement was found at surgery, although a metachronous multiglandular involvement causing recurrence after selective parathyroidectomy occurred in 17.6% of cases, after a mean disease-free interval of 13.7 years (range 5–27). Parathyroid carcinoma, atypical parathyroid adenoma, and jaw tumor occurred in one case; uterine involvement in 61.5% of women; other associated neoplasms were thyroid carcinoma (two cases) and renal and colon carcinoma (one case). Immunohistochemistry confirmed the loss of Parafibromin as the distinctive feature of the disease both in parathyroid and uterine tumors.

Conclusions

HPT–JT has a frequent single-gland parathyroid involvement and a relatively increased risk of parathyroid carcinoma. The penetrance of the disease is high but incomplete. Regardless of the denomination of the syndrome, jaw tumors occur rarely, while uterine involvement is frequently present. Selective parathyroidectomy may be an effective strategy, but a prolonged follow-up is required because of the risk of recurrences and malignancies. A systematic investigation is also required because of associated malignancies.

Carling T, Udelsman R (2005) Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med 257:27–37. doi:10.1111/j.1365-2796.2004.01428.x PubMedCrossRef

Cetani F, Pardi E, Borsari SL et al (2004) Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 89:5583–5591. doi:10.1210/jc.2004-0294 PubMedCrossRef

Carpten JD, Robbins CM, Villablanca A et al (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32:676–680. doi:10.1038/ng1048 PubMedCrossRef

Bradley KJ, Hobbs MR, Buley ID et al (2005) Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med 257:18–26. doi:10.1111/j.1365-2796.2004.01421.x PubMedCrossRef

Jackson CE, Norum RA, Boyd SB et al (1990) Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 108:1006–1012PubMed

Shattuck TM, Valimaki S, Obara T et al (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722–1729. doi:10.1056/NEJMoa031237 PubMedCrossRef

Porzionato A, Macchi V, Barzon L et al (2006) Immunohistochemical assessment of parafibromin in mouse and human tissues. J Anat 209:817–827. doi:10.1111/j.1469-7580.2006.00657.x PubMedCrossRef

Gill AJ, Clarkson A, Gimm O et al (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT–JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30:1140–1149. doi:10.1097/01.pas.0000209827.39477.4f PubMed

Juhlin C, Larsson C, Yakoleva T et al (2006) Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr-Relat Cancer 13:509–523. doi:10.1677/erc.1.01058 PubMedCrossRef

10.

Bradley KJ, Cavaco BM, Bowl MR et al (2006) Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol (Oxf) 64:299–306. doi:10.1111/j.1365-2265.2006.02460.x CrossRef

11.

Iacobone M, Barzon L, Porzionato A et al (2007) Parafibromin expression, single-gland involvement and limited parathyroidectomy in familial isolated hyperparathyroidism. Surgery 142:984–991. doi:10.1016/j.surg.2007.09.029 PubMedCrossRef

12.

Masi G, Barzon L, Iacobone M et al (2008) Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocr-Relat Cancer 15:1115–1126. doi:10.1677/ERC-08-0066 PubMedCrossRef

13.

DeLellis RA, Lloyd RV, Heitz PU, Heng C (2004) World Health Organization Classification of Tumours Pathology and Genetics: tumours of endocrine organs. IARC, Lyon

14.

Iacobone M, Lumachi F, Favia G (2004) Up-to-date on parathyroid carcinoma: analysis of an experience of 19 cases. J Surg Oncol 88:223–228. doi:10.1002/jso.20152 PubMedCrossRef

15.

Iacobone M, Ruffolo C, Lumachi F, Favia G (2005) Results of iterative surgery for persistent and recurrent parathyroid carcinoma. Langenbecks Arch Surg 390:385–390. doi:10.1007/s00423-005-0555-6 PubMedCrossRef

16.

Sarquis MS, Silveira LG, Pimenta FJ et al (2008) Familial hyperparathyroidism: surgical outcome after 30 years of follow up in three families with germline HRPT2 mutations. Surgery 143:630–640. doi:10.1016/j.surg.2007.12.012 PubMedCrossRef

17.

Howell VM, Haven CJ, Kahnoski K et al (2003) HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40:657–663. doi:10.1136/jmg.40.9.657 PubMedCrossRef

18.

Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ (2004) Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 89:96–102. doi:10.1210/jc.2003-030675 PubMedCrossRef

19.

Villablanca A, Calender A, Forsberg L et al (2004) Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet 41:e32. doi:10.1136/jmg.2003.012369 PubMedCrossRef

20.

Cavaco BM, Guerra L, Bradley KJ et al (2004) Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder mutation of the HRPT2 gene. J Clin Endocrinol Metab 89:1747–1752. doi:10.1210/jc.2003-031016 PubMedCrossRef

21.

Howell VM, Zori RT, Stalker HJ et al (2004) A molecular diagnosis of hyperparathyroidism-jaw tumor syndrome in an adolescent with recurrent kidney stones. J Pediatr 145:567. doi:10.1016/j.jpeds.2004.04.023 PubMedCrossRef

22.

Gimm O, Lorenz K, Nguyen Thanh P et al (2006) Das Familiäre Nebenschilddrüsenkarzinom. Indikation zur prophylaktischen Parathyreoidektomie? Chirurg 77:15–24. doi:10.1007/s00104-005-1110-2 PubMedCrossRef

23.

Moon SD, Park JH, Kim EM et al (2005) A novel IVS2–1G>A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 90:878–883. doi:10.1210/jc.2004-0991 PubMedCrossRef

24.

Mizusawa N, Uchino S, Iwata T et al (2006) Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf) 65:9–16. doi:10.1111/j.1365-2265.2006.02534.x CrossRef

25.

Aldred MJ, Talacko AA, Savarirayan R et al (2006) Dental findings in a family with hyperparathyroidism-jaw tumor syndrome and a novel HRPT2 gene mutation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101:212–218. doi:10.1016/j.tripleo.2005.06.011 PubMedCrossRef

26.

Guarnieri V, Scillitani A, Muscarella LA et al (2006) Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J Clin Endocrinol Metab 91:2827–2832. doi:10.1210/jc.2005-1239 PubMedCrossRef

27.

Kelly TG, Shattuck TM, Reyes-Mugica M et al (2006) Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res 21:1666–1671. doi:10.1359/jbmr.060702 PubMedCrossRef

28.

Yamashita Y, Akiyama T, Mizusawa N, Yoshimoto K, Goto M (2007) A case of hyperparathyroidism-jaw tumour syndrome found in the treatment of an ossifying fibroma in the maxillary bone. Int J Oral Maxillofac Surg 36:365–369. doi:10.1016/j.ijom.2006.08.007 PubMedCrossRef

29.

Cetani F, Pardi E, Ambrogini E et al (2007) Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation. Endocr-Relat Cancer 14:493–499. doi:10.1677/ERC-06-0092 PubMedCrossRef

30.

Cetani F, Ambrogini E, Viacava P et al (2007) Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol 156:547–554. doi:10.1530/EJE-06-0720 PubMedCrossRef

31.

Raue F, Haag C, Frank-Raue K (2007) Hyperparathyroidism-jaw tumor syndrome. A hereditary form of primary hyperparathyroidism with parathyroid carcinoma. Dtsch Med Wochenschr 132:1459–1462. doi:10.1055/s-2007-982052 PubMedCrossRef

32.

Cetani F, Pardi E, Ambrogini E et al (2008) Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment. J Endocrinol Investig 31:900–904

33.

Guarnieri V, Bisceglia M, Bonfitto N et al (2008) Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery 144:839–840. doi:10.1016/j.surg.2008.08.008 PubMedCrossRef

34.

Howell VM, Gill A, Clarkson A, Nelson AE et al (2009) Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 94:434–441. doi:10.1210/jc.2008-1740 PubMedCrossRef

35.

Iacobone M, Barzon L, Porzionato A et al (2009) The extent of parathyroidectomy for HRPT2-related hyperparathyroidism. Surgery 145:250–251. doi:10.1016/j.surg.2008.06.027 PubMedCrossRef

36.

Barry MK, van Heerden JA, Grant CS, Thompson GB, Khosla S (1997) Is familial hyperparathyroidism a unique disease? Surgery 122:1028–1033. doi:10.1016/S0039-6060(97)90205-1 PubMedCrossRef

37.

Huang SM, Duh QY, Shaver J, Siperstein AE, Kraimps JL, Clark OH (1997) Familial hyperparathyroidism without multiple endocrine neoplasia. World J Surg 21:22–28. doi:10.1007/s002689900188 PubMedCrossRef

38.

Carneiro DM, Irvin GL, Inabnet WB (2002) Limited versus radical parathyroidectomy in familial isolated primary hyperparathyroidism. Surgery 132:1050–1054. doi:10.1067/msy.2002.128695 PubMedCrossRef

39.

Evans DB, Rich TA, Cote GJ (2007) Surgical management of familial hyperparathyroidism. Ann Surg Oncol 14:1525–1527. doi:10.1245/s10434-006-9282-7 PubMedCrossRef

40.

Simonds WF, James-Newton LA, Agarwal SK et al (2002) Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 81:1–26. doi:10.1097/00005792-200201000-00001 CrossRef

Title: Hyperparathyroidism–jaw tumor syndrome: a report of three large kindred
Authors: Maurizio Iacobone
Giulia Masi
Luisa Barzon
Andrea Porzionato
Veronica Macchi
Francesco Antonio Ciarleglio
Giorgio Palù
Raffaele De Caro
Giovanni Viel
Gennaro Favia
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: Langenbeck's Archives of Surgery / Issue 5/2009
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-009-0511-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hyperparathyroidism–jaw tumor syndrome: a report of three large kindred

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2009

Is minimally invasive parathyroidectomy without QPTH monitoring justified?

How to perform a thyroidectomy in an outpatient setting

Evaluation of Halle, Miami, Rome, and Vienna intraoperative iPTH assay criteria in guiding minimally invasive parathyroidectomy

The effectiveness of FloSeal® matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study

Positional statement of the European Society of Endocrine Surgeons (ESES) on modern techniques in pHPT surgery

Imaging for primary hyperparathyroidism—an evidence-based analysis